180 Degree Capital is a closed-end management investment company. The company operates as an internally managed investment company. The company invests in both short- and long-term United States government and agency securities. To the extent that the company invests in short- and long-term United States government and agency securities, changes in interest rates result in changes in the value of these obligations that result in an increase or decrease of its net asset value. The company is focused on investing in undervalued microcapitalization publicly traded companies.

Acacia Research invests in intellectual property, and related absolute return assets and engages in the licensing and enforcement of patented technologies. The company partners with inventors and patent owners, from small entities to large corporations, applying its legal and technology capabilities to patent assets to unlock the financial value in their patented inventions. The company is an intermediary in the patent marketplace. The company has partnered with patent owners, including individual inventors, universities, small companies and large multi-national corporations in a variety of technology sectors.

Air T is a holding company. Through its subsidiaries, the company operates the following industry segments: overnight air cargo, which operates in the air express delivery services industry; ground equipment sales, which manufactures and provides mobile deicers and other equipment products; ground support services, which provides ground support equipment maintenance and facilities maintenance services; commercial aircraft, engines and parts, which provides services including commercial aircraft disassembly/part-out services; and printing equipment and maintenance, which designs, manufactures and sells digital print production equipment and provides maintenance services to commercial customers.

AquaBounty Technologies is a biotechnology company focused on improving productivity and sustainability in the aquaculture market. The company is conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins. The company has obtained the licensing rights for a gene construct (transgene) used to create a breed of farm-raised Atlantic salmon. The company has approval for the production, sale, and consumption of its AquAdvantage Salmon product in the United States; for the sale and consumption of its AquAdvantage Salmon product in Canada; and for the production of the product.

Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. The company is developing its lead product candidates, ARV-110 and ARV-471, into Phase 1 clinical trials. The company has initiated a Phase 1 clinical trial for ARV-110 in men with metastatic castration-resistant prostate cancer. The company is developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of women with locally advanced or metastatic ER positive / HER2 negative breast cancer.

CytomX Therapeutics is clinical-stage, oncology-focused biopharmaceutical company with a class of investigational antibody therapeutics based on its Probody? technology platform the treatment of cancer. The company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets. The company's two programs, CX-072, a wholly owned PD-L1-targeting Probody therapeutic and CX-2009, wholly owned CD166-targeting Probody drug conjugate. Both CX-072 and CX-2009 are part of PROCLAIM (Probody Clinical Assessment in Man), an international umbrella clinical trial program that provides clinical trial sites with access to the company's novel therapies under one central protocol.

First Internet Bancorp is a bank holding company. Through its subsidiary, First Internet Bank of Indiana, the company provides a range of commercial, small business, consumer and municipal banking products and services. The company conducts its consumer and small business deposit operations through online channels on a nationwide basis. The company's residential mortgage products are provided nationwide primarily through an online direct-to-consumer platform and are supplemented with Central Indiana-based mortgage and construction lending. The company's consumer lending products are primarily originated on a nationwide basis over the Internet as well as through relationships with dealerships and financing partners.

Foot Locker is a retailer of athletically inspired shoes and apparel. The company's reportable segments are: North America and International. The company's North America operating segment includes the following banners operating in the U.S. and Canada: Foot Locker, Kids Foot Locker, Lady Foot Locker, Champs Sports, Footaction, and SIX:02, including each of their related e-commerce businesses, as well as its Eastbay business that includes internet, catalog, and team sales. The company's International operating segment includes the following banners operating in Europe, Asia, Australia, and New Zealand: Foot Locker, Runners Point, Sidestep, and Kids Foot Locker, including each of their related e-commerce businesses.

GameStop is a multichannel video game and licensed consumer products retailer. The company's products and services includes: New Video Game Hardware, which provides video game platforms from manufacturers; New Video Game Software, which provides new video game software for existing and certain prior generation consoles from manufacturers, including Sony, Nintendo and Microsoft; Video Game Accessories, which consist primarily of controllers, gaming headsets, virtual reality products, and memory cards; and Digital, which sells a variety of digital currency and has developed technology to sell downloadable content and full-game downloads in its stores and on its U.S. website.

Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

Jack Henry & Associates is a provider of information processing solutions for community banks. The company's range of products and services includes processing transactions, automating business processes, and managing information for financial institutions and corporate entities. The company's proprietary solutions are marketed through three primary business brands: Jack Henry Banking, which is a provider of integrated data processing systems; Symitar, which is a provider of data processing solutions for credit unions of various sizes; and ProfitStars, which is a provider of agnostic products and services to financial institutions that are primarily not main customers of the company

Kewaunee Scientific is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. The company's products include steel, wood, and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. The company's operations are classified into two business segments: Domestic, which designs, manufactures, and installs scientific and technical furniture; and International, which provides facility design, detailed engineering, construction, and project management.

Lexicon Pharmaceuticals is a biopharmaceutical company. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is developing Zynquista? (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. The company is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. The company is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Liquidity Services is engaged in operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an automated environment. The company's reportable segments are: Retail Supply Chain Group, which consists of marketplaces that enable corporations to sell surplus and salvage consumer goods and retail capital assets; Capital Assets Group, which provides solutions to sellers and it consists of marketplaces that enable commercial businesses to sell surplus, salvage, and scrap assets; GovDeals, which provides self-directed service solutions; and Machinio, which operates an online platform for listing used equipment for sale in the construction, machine tool, among others.

Live Oak Bancshares is a bank holding company. Through its subsidiary, Live Oak Banking Company (the Bank), the company is engaged in providing lending and deposit related services. The company directly or indirectly holds the following wholly-owned subsidiaries: Canapi Advisors, LLC, which provides investment advisory services; Live Oak Ventures, Inc., which invests in businesses that align with the company's initiative in financial technology; Live Oak Grove, LLC, which provides an on-site restaurant location; Government Loan Solutions, Inc., which is a management and technology consulting firm; and 504 Fund Advisors, LLC, which serves as the investment advisor to the 504 Fund, a closed-end mutual fund.

Marrone Bio Innovations makes bio-based pest management and plant health products. Bio-based products are comprised of naturally occurring microorganisms, such as bacteria and fungi, and plant extracts. The company primarily sells its products to the crop protection market and also have one plant health product, Haven, that reduces plant stress in drought and intense sunlight. The company's product lines are Regalia, for controlling plant disease and increasing plant health, Grandevo and Venerate, for insect and mite control, Majestene and its turf and ornamentals counterpart brand Zelto, for nematode control and Stargus and its row crop counterpart brand Amplitude, for downy mildew and white mold control.

MasterCraft Boat Holdings is a holding company. Through its subsidiaries, the company is a designer, manufacturer, and marketer of recreational powerboats sold under MasterCraft, NauticStar, Crest, and Aviara brands. The company's segments include: MasterCraft, which produces MasterCraft and Aviara boats for water skiing, wakeboarding, wake surfing, and general recreational boating; NauticStar, which produces boats for saltwater fishing and general recreational boating; and Crest, which produces pontoon boats which are primarily used for general recreational boating. In addition, the company provides various accessories, including trailers and aftermarket parts.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's pipeline consists of two clinical-stage product candidates, maralixibat and volixibat, with mechanisms of action that have potential utility across a wide range of orphan liver diseases.

Mistras Group is a provider of technology-enabled asset protection solutions used to evaluate the safety, structural integrity and reliability of critical energy, industrial and public infrastructure. The company combines products and technologies, mechanical integrity, non-destructive testing, destructive testing, mechanical and predictive maintenance services, process and fixed asset engineering and consulting services, proprietary data analysis and enterprise inspection database management and analysis software, Plant Condition Management Software, to deliver a portfolio of customized solutions, ranging from routine inspections to asset integrity management and assessments.

Mustang Bio is a clinical-stage biopharmaceutical company. In partnership with St. Jude Children's Research Hospital, the company's gene therapy program (MB-107) is being developed to treat X-linked severe combined immunodeficiency. The company is developing chimeric antigen receptor engineered T cell therapies for hematologic malignancies in partnership with the City of Hope National Medical Center targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Research Center targeting CD20 (MB-106). In addition, The company has partnered with Nationwide Children's Hospital for C134 (MB-108) in order to improve the activity of MB-101 for the treatment of patients with glioblastoma multiforme.

MVB Financial is a financial holding company. Through its subsidiaries, the company provides community banking and mortgage banking. The company's subsidiary, MVB Bank, Inc. (The Bank), provides products and services, including: demand deposit accounts, savings accounts, money market accounts, and certificates of deposit; commercial, consumer, and real estate mortgage loans and lines of credit; cashier's checks; safe deposit rental facilities; and non-deposit investment services. The Bank's financial products and services are provided through its financial service locations and automated teller machines, as well as telephone and internet-based banking through both personal computers and mobile devices.

NeoPhotonics develops, manufactures and sells optoelectronic products that transmit, receive and switch high-speed digital optical signals for Cloud and data center internet content provider and telecom networks. The company focuses on products that operate at speed over distance, for 100 Gigabits per Second (G), 200G, and 400G and above data rates, such as at 600G and 800G. The company produces transmitter and receiver components and modules, as well as switching products, for 100G and beyond transmission over distances of two to 2,000 kilometers. The company integrates transmitter and receiver components into next generation pluggable transceiver modules.

Odonate Therapeutics is a pharmaceutical company focused on the development of therapeutics that improve and extend the lives of patients with cancer. The company's initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. In patients with metastatic breast cancer, tesetaxel was shown to have single-agent antitumor activity in two multicenter, Phase 2 studies. The company is conducting a multinational, multicenter, randomized, Phase 3 study in patients with locally advanced or metastatic breast cancer, known as CONTESSA.

PennantPark Investment is a closed-end, externally managed, non-diversified investment company. The company's objectives are to generate both current income and capital appreciation while seeking to preserve capital through debt and equity investments primarily made to United States middle-market companies in the form of first lien secured debt, second lien secured debt and subordinated debt and equity investments.

Pulse Biosciences is a bioelectric medicine company. The company is pursuing regulatory clearance to market CellFX? System (CellFX). The CellFX System utilizes its Nano-Pulse Stimulation? (NPS) technology to treat various applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nanosecond duration pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The company's CellFX System allows for the adjustment of four key treatment parameters: pulse duration, pulse amplitude, pulse frequency, and the number of pulses, depending on the target tissue, application and desired treatment outcome.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.

United Insurance Holdings is a holding company. Through its subsidiaries, the company is engaged in the residential personal and commercial property and casualty insurance business in the United States. The company's insurance subsidiaries provide personal residential and commercial property and casualty insurance products that protect its policyholders against losses due to damages to structures and their contents. Some of the company's insurance subsidiaries sell policies that protect against liability for accidents as well as property damage. The company's non-insurance subsidiaries support its insurance and investment operations. The company writes in Florida, Connecticut, Georgia, Hawaii, Louisiana, and other various states.

Vistra Energy operates an integrated retail and generation business in markets throughout the U.S. Through its subsidiaries, the company is engaged in electricity market activities, including electricity generation, wholesale energy sales and purchases, commodity risk management and retail sales of electricity. The company has six segments: Retail, ERCOT, PJM, NY/NE (comprising NYISO and ISO-NE), MISO and Asset Closure. The Retail segment is engaged in retail sales of electricity and related services. The ERCOT, PJM, NY/NE and MISO segments are engaged in electricity generation, among others. The Asset Closure segment is engaged in the decommissioning and reclamation of retired plants and mines.

vTv Therapeutics is a holding company. Through its subsidiaries, the company is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. The company's drug candidate for the treatment of Alzheimer's disease, azeliragon (TTP488), is an orally administered small molecule antagonist targeting the receptor for advanced glycation endproducts. The company's type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor. The company is also developing TTP399 for type 1 diabetes.